<DOC>
	<DOCNO>NCT02848105</DOCNO>
	<brief_summary>aGVHD remain complication patient allogeneic stem cell transplantation . Methylprednisolone 1~2mg/kg consider standard first-line treatment . In recent lab study , demonstrate valproic acid ( VPA ) histone deacetylase inhibitor inhibit CD4+ Th1 Th17 cell control aGVDH mouse model preserve GVL effect . In study , test hypothesis add VPA standard dose steroid treatment may improve outcome aGVHD .</brief_summary>
	<brief_title>Valproic Acid With Methylprenisonlone Treatment Acute GVHD</brief_title>
	<detailed_description>To evaluate complete response rate VPA+Methylpednisolone patient Grade II-IV aGVHD allogenetic stem cell transplantation .</detailed_description>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Grade IIIV aGVHD No previous history allergy valproic acid No active severe infection Inclusion clinical trial GVHD Prophylaxis valproic acid severe organ dysfunction : heart , lung , liver kidney</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>aGVHD</keyword>
	<keyword>valproic acid</keyword>
</DOC>